BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35193644)

  • 1. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    Yu J; Gao G; Wei X; Wang Y
    BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma.
    Chien CH; Yang WB; Chuang JY; Lee JS; Liao WA; Huang CY; Chen PY; Wu AC; Yang ST; Lai CC; Chi PI; Chu JM; Cheng SM; Liu CC; Hwang DY; Chen SH; Chang KY
    J Exp Clin Cancer Res; 2022 Jul; 41(1):220. PubMed ID: 35831908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs.
    Bashiri H; Moazam-Jazi M; Karimzadeh MR; Jafarinejad-Farsangi S; Moslemizadeh A; Lotfian M; Karam ZM; Kheirandish R; Farazi MM
    Immunotherapy; 2023 Oct; 15(14):1157-1169. PubMed ID: 37584216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
    Xu JX; Yang Y; Zhang X; Luan XP
    Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.
    Xia Q; Liu L; Li Y; Zhang P; Han D; Dong L
    Cancer Invest; 2021 Sep; 39(8):627-644. PubMed ID: 34254870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
    Guo L; Wu Z
    Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
    Hong B; Yang E; Su D; Ju J; Cui X; Wang Q; Tong F; Zhao J; Yang S; Cheng C; Xin L; Xiao M; Yi K; Zhan Q; Ding Y; Xu H; Cui L; Kang C
    Neuro Oncol; 2024 Jan; 26(1):100-114. PubMed ID: 37651725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
    Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
    J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
    Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
    NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
    Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
    Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
    Zeng H; Yang Z; Xu N; Liu B; Fu Z; Lian C; Guo H
    Cell Death Dis; 2017 Jun; 8(6):e2885. PubMed ID: 28617438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma stem cells resistant to temozolomide-induced autophagy.
    Fu J; Liu ZG; Liu XM; Chen FR; Shi HL; Pangjesse CS; Ng HK; Chen ZP
    Chin Med J (Engl); 2009 Jun; 122(11):1255-9. PubMed ID: 19567133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.